4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
4.260
+0.040 (0.95%)
Jul 21, 2025, 2:03 PM - Market open
4D Molecular Therapeutics Employees
4D Molecular Therapeutics had 227 employees as of December 31, 2024. The number of employees increased by 80 or 54.42% compared to the previous year.
Employees
227
Change (1Y)
80
Growth (1Y)
54.42%
Revenue / Employee
$101
Profits / Employee
-$777,264
Market Cap
197.34M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 227 | 80 | 54.42% |
| Dec 31, 2023 | 147 | 7 | 5.00% |
| Dec 31, 2022 | 140 | 16 | 12.90% |
| Dec 31, 2021 | 124 | 41 | 49.40% |
| Dec 31, 2020 | 83 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
FDMT News
- 9 days ago - 4DMT Announces New Employment Inducement Grants - GlobeNewsWire
- 18 days ago - 4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution - GlobeNewsWire
- 7 weeks ago - 4DMT to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - 4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewsWire
- 2 months ago - 4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME - GlobeNewsWire
- 4 months ago - 4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD - GlobeNewsWire
- 5 months ago - 4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewsWire
- 5 months ago - 4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression - Seeking Alpha